NEW YORK, Sept. 23, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that a poster highlighting Iomab-B, its pivotal Phase 3 targeted conditioning candidate, was awarded Honorable Distinction at the 2019 SOHO (Society of Hematologic Oncology) Annual Meeting. SOHO is the only international society specific

BOSTON, Sept. 23, 2019 /PRNewswire/ -- Six in 10 Americans rate oral health as either "fair," "poor," or "very poor," according to independent research commissioned by DentaQuest and conducted by KRC Research. Further, more than half of patients (51%) are concerned about their oral health, making it the top health concern over heart, eye, digestive, mental, and skin heal

LAVAL, QC and SEATTLE, Sept. 23, 2019 /PRNewswire/ - Today, our merged affiliates, NEOMED-LABS, Pacific Biomarkers and PAIRimmune, are proud to announce the launch of our new international name, Nexelis, along with our unified vision and capabilities.

NEW YORK and CAESAREA, Israel, Sept. 23, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, today announced that Erez Raphael

BOSTON, Sept. 23, 2019 /PRNewswire/ -- Sagentia, the global product development and technology consultancy and a Science Group company, announces the launch of MediTheatre, its Virtual Reality 'showroom'. Delegates at The MedTech Conference in Boston on September 23rd-25th, will be the first to in

ROME, Sept. 23, 2019 /PRNewswire/ -- Promising results from the preclinical study conducted by Menarini Ricerche on MEN1611, a potent and selective orally available phosphatidylinositol 3-kinase (PI3K) inhibitor currently in development for the treatment of breast cancer. The poster entitled "Characterization of the mechanism of action and efficacy of MEN1611, a novel

BOSTON, Sept. 23, 2019 /PRNewswire/ -- FogPharma today announced the appointment of Fang Wang, Ph.D., as Vice President of Biology and Nancy Wilker, Ph.D., J.D., as Vice

SAN DIEGO, Sept. 23, 2019 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced positive topline results from the "STAR Study", a Phase 2 dose-ranging study of tolperisone in acute muscle spasms of the back. The primary objective of the study was to assess the efficacy of

TUCSON, Ariz., Sept. 23, 2019 /PRNewswire/ -- UAVenture Capital, a Tucson-based venture capital fund dedicated to the commercialization of discovery products, technology and services emerging from the University of Arizona, today announced its third and fourth investments for Fund II, its eighth and ninth

HONOLULU, Sept. 23, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) today announced results from the pre-specified interim review of its ongoing CHASE (Cardiovascular Health Astaxanthin Supplement Evaluation) clinical trial. The CHASE clinical trial is a double-blind, randomized, placebo-controlled clinical trial evaluating the e